Chemistry:Volagidemab
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | REMD-477; AMG-477 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Volagidemab (development name REMD-477) is a monoclonal antibody that targets the glucagon receptor. It is developed by REMD Biotherapeutics for type 1 and type 2 diabetes. A phase II trial did not meet its primary endpoint.[1][2][3]
References
- ↑ Pettus, Jeremy; Reeds, Dominic; Cavaiola, Tricia S.; Boeder, Schafer; Levin, Michelle; Tobin, Garry; Cava, Edda; Thai, Dung et al. (May 2018). "Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial". Diabetes, Obesity and Metabolism 20 (5): 1302–1305. doi:10.1111/dom.13202. PMID 29283470.
- ↑ Pettus, Jeremy; Boeder, Schafer C.; Christiansen, Mark P.; Denham, Douglas S.; Bailey, Timothy S.; Akturk, Halis K.; Klaff, Leslie J.; Rosenstock, Julio et al. (1 June 2021). "236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial". Diabetes 70 (Supplement_1). doi:10.2337/db21-236-OR.
- ↑ Pettus, Jeremy; Boeder, Schafer C.; Christiansen, Mark P.; Denham, Douglas S.; Bailey, Timothy S.; Akturk, Halis K.; Klaff, Leslie J.; Rosenstock, Julio et al. (October 2022). "Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial". Nature Medicine 28 (10): 2092–2099. doi:10.1038/s41591-022-02011-x. PMID 36192552.
 |  |
